UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
------------------------
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
------------------------
Date of Report (Date of earliest event reported): September 9, 2003
IMPAX LABORATORIES, INC.
----------------------------------------------------------------
(Exact name of Registrant as specified in its charter)
Delaware 0-27354 65-0403311
- ------------------------------- ----------------- ----------------------
(State or other jurisdiction of (Commission (I.R.S. Employer
incorporation or organization) File Number) Identification Number)
30381 Huntwood Avenue
Hayward, CA 94544
------------------------------------------------------------
(Address of principal executive offices, including zip code)
Registrant's telephone number, including area code: (510) 476-2000
--------------
Item 9. Regulation FD Disclosure
On September 9, 2003, Impax Laboratories Inc. issued a press release
announcing that Alza Corporation, a unit of Johnson & Johnson, had commenced
litigation against the Company in the United States District Court, Northern
District of California related to the Company's generic version of Ditropan XL
(Oxybutynin Chloride) Tablets, 15 mg. A copy of the press release is attached as
Exhibit 99.1 and is incorporated herein by reference.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Impax Laboratories, Inc.
Date: September 9, 2003
By: Cornel C. Spiegler
-----------------------------
Cornel C. Spiegler
Chief Financial Officer